Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 11c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.68), $0.11 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $32.41 million versus the consensus estimate of $49.23 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• DA Davidson Reiterates Buy Rating on Wabash National (WNC)
• Bernstein SocGen on StandardAero Inc (SARO): ' Solid revenues, but short-term margin issues'